This medication is commonly used to help with symptoms related to physical discomfort and inflammatory or irritative states. It is applied across domains where short-term symptomatic assistance is needed.

---

Easing

ightarrow Sudden or Worsening Discomfort

This medicine is considered relevant in clinical settings that involve acute or unstable symptom patterns, such as those associated with sudden or episodic changes. It provides support that helps ease the overall symptom burden, may support patients during episodes of heightened discomfort that interfere with daily functioning. Common indications include addressing symptoms related to physical discomfort and applied in conditions presenting with systemic or localized discomfort.

“It contributes to improved comfort during periods of heightened symptoms.”

---

Supportive Care

ightarrow Managing Symptom Clusters

It is applied in addressing conditions involving episodic or fluctuating manifestations, often when groups of symptoms appear suddenly or cluster into patterns. This support may assist with supporting general well-being during symptomatic phases and coping more steadily with symptom fluctuations. This agent is relevant for easing symptoms that create noticeable physiological strain, providing supportive relief in contexts where temporary symptom management is appropriate.

Quick Fact: Addressing Acute Symptom Patterns The medication is relevant when symptoms escalate temporarily and short-term symptomatic assistance is needed for symptom clusters.

Regulatory References

1. NIH MedlinePlus Drug Information

This section explains, based on official regulatory documents, the patient populations for whom use of this medicine is restricted or prohibited. Cataflam DD contains diclofenac potassium, an NSAID.

Populations Who Must Not Use (Contraindicated)

Use is formally contraindicated (prohibited) in patients with the following conditions or states:

• Hypersensitivity: Known allergy to diclofenac or any components, or a history of asthma, hives (urticaria), or allergic-type reactions after taking aspirin or other NSAIDs.
• Gastrointestinal Disease: Active stomach or intestinal ulceration, bleeding, or perforation.
• Severe Organ Failure: Diagnosed severe hepatic (liver) failure or severe renal (kidney) failure (GFR <15 mL/min/1.73 m^2).
• Cardiovascular Status: Severe cardiac failure, established congestive heart failure (NYHA class II-IV), or for the treatment of pain right before or after coronary artery bypass graft (CABG) surgery.
• Pregnancy: During the last trimester of pregnancy (after 30 weeks of gestation).

Restricted or Not Recommended Use

• Cardiovascular: High-dose (e.g., >100 mg/day) and long-term use is generally not recommended for patients with established cardiovascular disease, uncontrolled hypertension, or significant cardiovascular risk factors. The lowest effective dose for the shortest duration possible should be used.
• Age: Use in children and adolescents below 14 years of age is typically not recommended for this specific tablet form. The elderly may also require caution due to increased risk of side effects.
• Pregnancy: Use is generally avoided after 20 weeks of gestation due to risk of fetal renal dysfunction and other complications.

Interactions with other medicines and products

Cataflam DD (diclofenac) can interact with several medicinal products, primarily by increasing the risk of serious side effects or by altering the effectiveness of co-administered drugs.

Combinations Requiring Caution or Avoidance

Interacting Product Category	Potential Outcome
Other NSAIDs or Aspirin	Significantly increased risk of serious gastrointestinal bleeding or ulceration. Concomitant use with other NSAIDs is generally avoided.
Anticoagulants (e.g., Warfarin)	Increased risk of hemorrhage or bleeding, requiring close monitoring of blood clotting.
Blood Pressure Medicines (e.g., ACE inhibitors, ARBs, Diuretics)	Reduced antihypertensive or diuretic effect; increased risk of kidney impairment, including acute renal failure. Close monitoring of kidney function and blood pressure is necessary.
Selective Serotonin Reuptake Inhibitors (SSRIs) and Systemic Corticosteroids	Increased risk of gastrointestinal bleeding.
Lithium	Increased plasma lithium levels due to reduced renal clearance of lithium, which can lead to toxicity. Requires monitoring of lithium levels.
Methotrexate	Increased plasma levels of methotrexate and potential for toxicity, particularly with higher doses.

Diclofenac is contraindicated for the treatment of peri-operative pain in the setting of Coronary Artery Bypass Graft (CABG) surgery due to the increased risk of heart attack and stroke. Concomitant use with strong enzyme inhibitors like voriconazole can increase diclofenac exposure. Patients with cardiovascular risk factors should use the lowest effective dose for the shortest duration possible.

How Cataflam DD Works: Mechanism of Action

Blocking Prostanoid Generation via Cyclooxygenase (COX) Inhibition

This mechanism centers on the active ingredient, diclofenac free acid, acting as a non-selective inhibitor of the Cyclooxygenase (COX-1 and COX-2) enzymes. It blocks the conversion of arachidonic acid into pro-inflammatory and pro-nociceptive signaling mediators, primarily prostaglandins ( PGE2).

Influence on Peripheral Nociceptive and Vasopressor Mediators

By lowering the local concentration of these mediators at the tissue damage site, the mechanism prevents the sensitization of peripheral nociceptors and limits the generation of mediators that promote local vasodilation and increased capillary permeability. This action results in a decrease in enhanced nociceptive transmission and fluid extravasation.

The Dual-Impact Mechanistic Domain

The non-selective action on COX-1 and COX-2 defines the full mechanistic scope. The inherent COX-1 inhibition alters housekeeping pathways that regulate the gastric mucosal barrier and control platelet aggregation via TXA2 synthesis.

How to Use Cataflam DD: Administration Guidelines

Cataflam DD (Diclofenac Potassium 50 mg immediate-release tablets) is strictly administered via the oral route. The medication is intended for short-term treatment only, and its usage is guided by the fundamental instruction to always use the lowest effective dose for the shortest duration possible to manage symptoms.

---

Dosing and Frequency Patterns

The total daily dose is typically administered in divided doses throughout the day, often two or three times. For general adult use, the daily dose usually ranges between 75 mg to 150 mg. While the usual maximum daily dose is 150 mg, guidelines indicate up to 200 mg per day in specific acute settings, such as for the management of migraine or primary dysmenorrhea.

For acute pain, an initial 50 mg dose may be taken at the onset of symptoms, followed by subsequent 50 mg doses as necessary to maintain relief, without exceeding the daily maximum.

---

Administration Requirements and Special Populations

Administration Requirement	Instruction
Tablet Intake	Must be swallowed whole with liquid; do not crush, chew, or break the tablets.
Timing Relative to Meals	May be taken with or after food to mitigate gastrointestinal discomfort, although taking on an empty stomach may lead to a faster onset of effect.
Adolescent Use	The 50 mg tablet is generally not recommended for children below 14 years of age. For adolescents 14 years, 75 mg to 100 mg daily is typically divided.
Older Adults	The lowest effective dose is strongly advised, though a specific starting dose adjustment is not mandated.

These instructions define the approach for using the medication.

Research evidence / Overview of studies for Cataflam DD

The clinical research for Cataflam DD (Diclofenac Potassium) has primarily focused on its evaluation in research scenarios involving short-term symptom activity, consistent with its formulation as an immediate-release medicine. The evidence overview below describes the types of studies conducted and the patterns observed in research findings, without making statements about clinical effectiveness or giving advice.

---

Evidence for Use in Acute Pain and Sudden Discomfort

The evidence base for this medicine's evaluation in acute pain and discomfort primarily consists of short-term Randomized Controlled Trials (RCTs) and Systematic Reviews that compare its use against an inactive substance or other pain relievers. Studies explored outcomes related to physical discomfort and were applied in studies examining patient-reported experiences using standardized scales.

Findings describe patterns observed in the studies, which focused on patient-reported outcomes describing perceived discomfort over defined time intervals. Studies reported how symptoms evolved in the observed populations, noting measured changes in patient pain scores within the initial few hours following administration. Results apply mainly to the populations studied in the research, which are generally healthy adults experiencing an acute, short-lived pain event.

---

Evidence for Use in Temporary Inflammation Response

This part of the overview describes the research landscape for conditions where discomfort is linked to an underlying inflammatory component. The medicine was evaluated in studies observing acute or unstable symptom patterns associated with inflammatory or irritative states. Researchers examined outcomes linked to inflammatory or irritative states, focusing on symptomatic support during periods of heightened symptom activity.

Regulatory assessments describe consistent patterns in how symptoms evolved in the observed adult populations during studies conducted during periods of increased symptom activity linked to inflammatory conditions. Research contributes to the broader evidence landscape for short-term symptomatic assistance in conditions characterized by acute or disruptive episodes.

---

What Is Still Uncertain About Cataflam DD Research

While the evidence for short-term evaluation in acute pain is substantial, several research limitations are noted in the scientific literature. Follow-up durations were limited across the primary efficacy studies, meaning the data provide only limited insight into how symptoms evolve over extended periods.

Comparative evidence is lacking for the specific Diclofenac Potassium formulation against all other NSAIDs, meaning direct head-to-head subgroup findings are uncertain. Furthermore, research does not determine whether an individual will respond similarly to the group patterns observed in the trials, and the long-term effects of the drug are not fully established.

Key Studies & References Diclofenac (Oral Route) Drug Information – NIH MedlinePlus

Common questions about Cataflam DD (FAQ)

Q: What conditions or types of pain is Cataflam DD approved to treat?

According to official regulatory documents, Cataflam DD (diclofenac potassium immediate-release) is indicated for the relief of mild to moderate pain. The drug is also approved for treating primary dysmenorrhea (menstrual pain) and for relieving the signs and symptoms associated with both osteoarthritis and rheumatoid arthritis.

Q: How long does the pain-relieving effect of Cataflam DD typically last?

Pharmacokinetic data indicates that the active compound, diclofenac, has an elimination half-life of approximately 1.2 to 2 hours. For some diclofenac formulations, research has reported improvements in pain lasting up to eight hours, but the duration of effect can vary based on the individual and the condition being addressed.

Q: Is it generally safe to consume alcohol while undergoing treatment with Cataflam DD?

Regulatory warnings describe that combining alcohol with this type of medicine (NSAIDs) is discouraged due to potential risks. This combination may significantly increase the risk of serious side effects involving the stomach and intestines, such as internal bleeding or ulceration.

Q: Is the active ingredient in Cataflam DD the same as the one in Voltaren?

The core active ingredient is the same (diclofenac), but the salt form is different. Cataflam DD contains diclofenac potassium, while many Voltaren products typically contain diclofenac sodium. The use of the potassium salt formulation is associated with differences in the speed of absorption compared to the sodium salt formulation.

Q: What is the maximum recommended number of days to take Cataflam DD continuously?

Regulatory guidelines emphasize that this medication is intended for short-term treatment only. The official instruction is to always use the lowest effective amount for the shortest duration necessary to control symptoms. A universal, specific maximum number of continuous days is generally not defined across all indications.

Q: Can Cataflam DD be used for types of headaches other than migraine?

Official labeling indicates the drug for the relief of mild to moderate pain generally. While its immediate-release formulation is also specifically studied for acute migraine, its broader indication covers various types of mild to moderate acute pain.

Q: Is Cataflam DD known to interact with herbal supplements?

Official product information emphasizes the importance of disclosing all other products used, including herbal supplements and vitamins, to a healthcare provider. Since safety information regarding complementary medicines and diclofenac may be limited, comprehensive disclosure is advised for proper medical oversight.

Q: Are there specific instructions for stopping the use of Cataflam DD after a course of treatment?

Regulatory guidance focuses on taking the drug only for the shortest time needed. There are no general instructions for gradually reducing the dose (tapering) when stopping this medication, but official warnings describe that immediate discontinuation may be necessary if serious adverse effects, such as confusion, occur.

Q: Does the medication increase sensitivity to sunlight or UV exposure?

Yes, official adverse reaction reports have associated diclofenac use with an increased sensitivity of the skin to sunlight, a reaction known as photosensitivity. The association with photosensitivity means individuals may need to consider precautions against excessive sun exposure.

Q: Does Cataflam DD interact with diabetes medications?

Official interaction warnings describe that diclofenac can affect how some oral hypoglycemic agents (diabetes medicines) work. This may increase the risk of related adverse events, such as lactic acidosis when taken with certain drugs like metformin. Monitoring of kidney function may be warranted when the two drug classes are used together.

Q: What are the signs of a potential high potassium level from taking this drug?

This class of medicine (NSAIDs) is known to potentially cause an increase in serum potassium levels, a condition called hyperkalemia. Official warnings indicate that symptoms of severely elevated potassium can include muscle weakness, a tingling sensation, or an irregular heart rhythm.

Q: Does Cataflam DD carry a risk of causing confusion or mood changes?

Regulatory warnings list side effects involving the central nervous system, including reports of confusion, drowsiness, and dizziness. Due to the potential for these central nervous system effects, official information notes that performance of tasks requiring alertness, such as driving or operating heavy machinery, may be impaired.

Official Storage and Disposal Requirements

Cataflam DD (diclofenac potassium) must be stored strictly according to official regulatory requirements to maintain its stability and effectiveness. The medication should be kept at Controlled Room Temperature, typically 20 C to 25 C (68 F to 77 F), with temporary excursions permitted up to 30 C.

Key Storage and Handling

Requirement	Official Instruction
Temperature	Store at Controlled Room Temperature.
Protection	Keep in the original, tight, light-resistant container and protect from moisture.
Safety	Keep the medication securely out of the reach of children.

Disposal Protocol

To dispose of unused or expired Cataflam DD, follow official government guidelines. Do not flush the medication down a toilet or pour it down a drain. Utilize a drug take-back program when available, or mix the medication with an unappealing substance like dirt or coffee grounds, seal it in a plastic bag, and place it in the household trash.